What is HER2 SISH?

What is HER2 SISH?

What is HER2 SISH?

SISH is an advantageous technique for the detection of gene amplification. The use of the SISH technique in breast carcinoma may be an alternative to other in situ hybridization (ISH) techniques however more detailed studies seem necessary to detect HER2 gene amplification in other human malignancies.

What is the survival rate for HER2-positive breast cancer?

The outlook for this type of cancer depends on things like the treatment you get and the stage of your cancer. But new treatments like chemotherapy plus trastuzumab have boosted early-stage HER2 positive breast cancer survival rates: 7-year disease-free: Around 93% 10-year disease-free: About 70%-75%

Is it better to be HER2 positive or negative?

Is HER2-positive breast cancer good or bad? HER2-positive cancer tends to be poorer in terms of prognosis than HER2-negative cancer because: It grows faster. It is more likely to spread to the lymph nodes fast.

What does HER2 CEP17 ratio mean?

The interpretation for HER2 FISH testing (HER2/CEP17 ratio and gene copy number) is given below: Positive HER2 amplification: FISH ratio is greater than 2.2 or HER2 gene copy is greater than 6.0. Equivocal HER2 amplification: FISH ratio of 1.8-2.2 or HER2 gene copy of 4.0-6.0.

Does HER2-negative require chemo?

Hormonal therapy is considered the standard initial treatment for HER2-negative metastatic breast cancer that is also hormone receptor-positive, and is often given in combination with targeted therapy. However, chemotherapy may also be given. A clinical trial may also be an option for treatment at any stage.

Is HER2 breast cancer fatal?

HER2-positive breast cancer is highly curable because of the availability of these HER2-targeted therapies, so we treat patients fairly aggressively upfront to reduce the risk of them experiencing a stage IV recurrence.

What happens if HER2 is negative?

In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface.